[Abstract] Murine tumor models have been critical to advances in our knowledge of tumor physiology and for the development of effective tumor therapies. Essential to these studies is the ability to both track tumor development and quantify tumor burden in vivo. For this purpose, the introduction of genes that confer tumors with bioluminescent properties has been a critical advance for oncologic studies in rodents. Methods of introducing bioluminescent genes, such as firefly luciferase, by viral transduction has allowed for the production of tumor cell lines that can be followed in vivo longitudinally over long periods of time. Here we describe methods for the production of stable luciferase expressing tumor cell lines by lentiviral transduction.
transduction limits the time over which cell tracking can be performed. This is especially problematic for oncology studies that may last several months. The ability of retroviruses to integrate into the genome is a key attribute that favors their use in producing stable cell lines. However, some oncoretroviruses, such as the Moloney murine leukemia virus can be limited by transgene silencing over time (Jähner et al., 1982) . Further, retroviral vectors require cell division for genomic integration and can be inefficient at transducing highly differentiated cells such as neurons, dendritic cells, or resting lymphocytes.
For the purpose of making luciferase expressing cell lines, lentiviral retroviral vectors derived from human immunodeficiency virus-1 (HIV-1) are highly effective. An advantage of lentiviral vectors over other retroviral vectors, is their ability to integrate into the genome of non-dividing cells. This property makes them suitable gene delivery vehicles for targeting highly differentiated cells, such as neurons, dendritic cells and lymphocytes (Naldini et al., 1996) . Lentiviruses also deliver very stable genomic integration and long-term transgene expression, to the extent that they have been used to make transgenic mice following embryo transduction (Lois et al., 2002) .
In order to track hematologic tumor cells in an in vivo murine leukemia model, we made the FULGW lentiviral vector that co-expresses firefly luciferase (Luc) and enhanced green fluorescent protein (EGFP) for the purpose of B-cell lymphoma (A20) cell line transduction and stable clone production. The FULGW vector is based on a self-inactivating vector previously described by Miyoshi et al. (1998) FULGW contains unique elements that enhance gene integration and expression ( Figure 1A ). It encodes the human immunodeficiency virus-1 (HIV-1) flap element, giving it karyotropic properties that permit efficient genomic integration in non-replicating cells (Zennou et al., 2000) . It contains the woodchuck hepatitis virus posttranscriptional regulatory element (WPRE) that increases gene expression by transcript stabilization (Zufferey et al., 1999) . In addition, it includes a 3' self-inactivating long terminal repeat (3' si-LTR) that contributes to maintaining it as a replication deficient virus. The 3' si-LTR was developed by the deletion of a 133 bp region in the U3 region (ΔU3) of the 3' LTR that renders the 5' LTR of the integrated provirus transcriptionally inactive (Miyoshi et al., 1998) .
Virus production is performed by the co-transfection of HEK-293T cells with the lentiviral plasmid (FULGW) and the two packaging plasmids, pCMV-ΔR8.91 and pCMV-VSVG ( Figure 1B ). HEK-293T cells are a human embryonic kidney cell line that stably expresses the CMV large T antigen, which greatly increases gene expression by the CMV promoter, generating robust virus production.
pCMVΔR8.91 is an HIV-1 Gag and Polymerase (Pol) expression plasmid that was modified from the dR8.9 vector by deletion of four accessory HIV-1 gents, Vif, Vpr, Vpu, and Nef (Zufferey et al., 1997) .
pCMV-VSVG expresses the pantropic envelop (Env) protein derived from the vesicular stomatitis virus glycoprotein (VSVG) (Stewart et al., 2003 d. Remove 2 ml of media from each plate (now 8 ml total).
e. Add 3 ml of the Lipofectamine/plasmid mix to each plate in a dropwise manner, evenly distributing the mix over the plate.
4. Incubate for 6 h at 37 °C, aspirate the media and add 10 ml of fresh D10. has been pre-wetted with 10 ml D10.
Concentrate the virus.

Note: Use proper containment when working with lentiviruses as per BSL-2 and institutional
guidelines.
a. Ultra-centrifugation method i. Put the SN in Beckman ultra-clear 25 x 89 mm tubes (each holds up to 35 ml) and weigh on a balance to the hundredth of a gram to insure they are of equal weight such that the rotor will be balanced.
ii. Spin at 25,000 rpm (112,000 x g) for 90 min at 4 °C in an SW-28 rotor.
Copyright © 2018 The Authors; exclusive licensee Bio-protocol LLC. ii. Centrifuge at 3,000 rpm (1811 x g) at 15 °C for 2-2.5 h using a table-top centrifuge.
iii. Discard flow through. h at 1,000 x g (~2,300 rpm on a table-top centrifuge).
2. Incubate at 37 °C for another 3 h, then replace the media with fresh culture media. c. Wait at least 2 min to allow cell lysis, then measure luminescence in a luminometer or an IVIS system ( Figures 3A and 3B ).
6. Select clones and retest for GFP and luciferase expression after two weeks of culture to insure stable integration of the transgenes.
7. Freeze and store multiple aliquots of the cell line in liquid nitrogen for future use. 
Data analysis
IVIS data is collected in regions of interest and can be exported to Excel spreadsheet for analysis.
The significance of differences between treatment groups can be determined by unpaired Student's t-test. 
